Research & Development

Merck Serono, Geneva, offers a globally integrated research organization with some 1,500 researchers presently working across ten sites all over the world.

In order to deliver high-value compounds, we are committed to standing for innovation in human health care based on scientific excellence and the highest ethical standards. Merck Serono’s innovative research will drive the next wave of new and efficacious therapies for patients with significant unmet medical needs.

Merck Serono research brings a balance of small molecules, proteins and monoclonal antibodies into the early clinical development pipeline. A broad base of technological expertise allows us to exploit the full potential of the biological and chemical spheres. The application of new technologies and a broader platform of therapeutic molecules, enhanced by combined experience, is a key factor for innovation.

An integrated drug discovery process allows for a disease-oriented approach, selecting the therapeutic method best suited to treat that disease. The objective is to bring the best compound to the clinic by a clear Proof-of-Concept strategic approach in order to obtain a confirmed mode of action on patients.

Merck Serono’s research strategy is further supported by a strong portfolio and business development in the discovery phase. A network of alliances with other biotech companies and academic groups enriches our disease knowledge and technological capabilities fostering a constant flow of innovations into the organization.

Merck Serono believes that a healthier future deserves a sizeable investment. The commitment to discovering and developing new therapies can be seen in the roughly 20% of total sales we devote to research and development activities, each year.

Our R&D pipeline is well-stocked with many promising candidates. In addition to our core therapy areas, we are exploring new therapeutic directions that will bring innovative treatment options to patients in areas of high unmet medical need.